DK3185867T3 - Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni - Google Patents
Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni Download PDFInfo
- Publication number
- DK3185867T3 DK3185867T3 DK15836431.5T DK15836431T DK3185867T3 DK 3185867 T3 DK3185867 T3 DK 3185867T3 DK 15836431 T DK15836431 T DK 15836431T DK 3185867 T3 DK3185867 T3 DK 3185867T3
- Authority
- DK
- Denmark
- Prior art keywords
- skizofrenia
- treatment
- extended release
- release formulations
- crystallization procedure
- Prior art date
Links
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical class ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title 1
- 238000002425 crystallisation Methods 0.000 title 1
- 230000008025 crystallization Effects 0.000 title 1
- 238000013265 extended release Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462041341P | 2014-08-25 | 2014-08-25 | |
PCT/US2015/046525 WO2016032950A1 (en) | 2014-08-25 | 2015-08-24 | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3185867T3 true DK3185867T3 (da) | 2021-03-15 |
Family
ID=55347322
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15836431.5T DK3185867T3 (da) | 2014-08-25 | 2015-08-24 | Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni |
Country Status (19)
Country | Link |
---|---|
US (4) | US10064859B2 (da) |
EP (2) | EP3185867B1 (da) |
JP (2) | JP6591546B2 (da) |
CN (2) | CN111454207A (da) |
AU (2) | AU2015306910B2 (da) |
CA (1) | CA2959329C (da) |
CY (1) | CY1124058T1 (da) |
DK (1) | DK3185867T3 (da) |
ES (1) | ES2862098T3 (da) |
HR (1) | HRP20210551T1 (da) |
HU (1) | HUE054641T2 (da) |
IL (1) | IL250661B (da) |
LT (1) | LT3185867T (da) |
MA (2) | MA40480B1 (da) |
PL (1) | PL3185867T3 (da) |
PT (1) | PT3185867T (da) |
RS (1) | RS61709B1 (da) |
SI (1) | SI3185867T1 (da) |
WO (1) | WO2016032950A1 (da) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
CN111454207A (zh) * | 2014-08-25 | 2020-07-28 | 奥克梅斯制药爱尔兰有限公司 | 用于治疗精神***症的缓释制剂中阿立哌唑衍生物的结晶方法 |
EP3294724A4 (en) * | 2015-05-08 | 2018-11-21 | Davuluri, Ramamohan Rao | Improved process for the preparation of aripiprazole with reduced particle size |
WO2018104953A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate |
ES2903278T3 (es) | 2017-07-28 | 2022-03-31 | Interquim Sa | Procedimiento para la preparación de aripiprazol lauroxil |
CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN113105389B (zh) * | 2021-04-16 | 2022-04-08 | 江苏海洋大学 | 一种阿立哌唑药物共晶及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
ES2315721T5 (es) * | 2003-10-23 | 2012-08-24 | Otsuka Pharmaceutical Co., Ltd. | Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento |
TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
CN105560176A (zh) | 2007-12-19 | 2016-05-11 | 詹森药业有限公司 | 与长效注射用帕潘立酮酯相关的给药方案 |
US20110003823A1 (en) | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
US8431576B2 (en) * | 2009-06-25 | 2013-04-30 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
WO2012077134A1 (en) * | 2010-12-07 | 2012-06-14 | Ind-Swift Laboratories Limted | Process for preparing aripiprazole polymorphs |
AU2012204174B2 (en) * | 2011-01-07 | 2016-07-21 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
IL296695A (en) * | 2011-03-18 | 2022-11-01 | Alkermes Pharma Ireland Ltd | Pharmaceutical preparations containing sorbitan esters |
WO2013142198A1 (en) * | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaaceutical compositions comprising fatty acid esters |
NZ730571A (en) * | 2012-09-19 | 2018-12-21 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
CN111454207A (zh) * | 2014-08-25 | 2020-07-28 | 奥克梅斯制药爱尔兰有限公司 | 用于治疗精神***症的缓释制剂中阿立哌唑衍生物的结晶方法 |
-
2015
- 2015-08-24 CN CN202010375290.3A patent/CN111454207A/zh active Pending
- 2015-08-24 SI SI201531576T patent/SI3185867T1/sl unknown
- 2015-08-24 ES ES15836431T patent/ES2862098T3/es active Active
- 2015-08-24 CA CA2959329A patent/CA2959329C/en active Active
- 2015-08-24 WO PCT/US2015/046525 patent/WO2016032950A1/en active Application Filing
- 2015-08-24 AU AU2015306910A patent/AU2015306910B2/en active Active
- 2015-08-24 US US14/833,638 patent/US10064859B2/en active Active
- 2015-08-24 DK DK15836431.5T patent/DK3185867T3/da active
- 2015-08-24 PL PL15836431T patent/PL3185867T3/pl unknown
- 2015-08-24 CN CN201580057857.XA patent/CN107106556B/zh active Active
- 2015-08-24 RS RS20210433A patent/RS61709B1/sr unknown
- 2015-08-24 EP EP15836431.5A patent/EP3185867B1/en active Active
- 2015-08-24 JP JP2017530956A patent/JP6591546B2/ja active Active
- 2015-08-24 MA MA40480A patent/MA40480B1/fr unknown
- 2015-08-24 MA MA055917A patent/MA55917A/fr unknown
- 2015-08-24 PT PT158364315T patent/PT3185867T/pt unknown
- 2015-08-24 HU HUE15836431A patent/HUE054641T2/hu unknown
- 2015-08-24 EP EP21150116.8A patent/EP3865476A1/en active Pending
- 2015-08-24 LT LTEP15836431.5T patent/LT3185867T/lt unknown
-
2017
- 2017-02-19 IL IL250661A patent/IL250661B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/043,721 patent/US10478434B2/en active Active
-
2019
- 2019-09-18 JP JP2019169473A patent/JP2019210296A/ja active Pending
- 2019-10-08 US US16/595,608 patent/US10973816B2/en active Active
-
2020
- 2020-11-04 AU AU2020264303A patent/AU2020264303B2/en active Active
-
2021
- 2021-03-24 US US17/211,352 patent/US11883394B2/en active Active
- 2021-04-07 HR HRP20210551TT patent/HRP20210551T1/hr unknown
- 2021-04-13 CY CY20211100318T patent/CY1124058T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3521282T3 (da) | Quinazolinderivater anvendt til behandling af hiv | |
DK3096741T3 (da) | Fremgangsmåde til fremstillingen af hybridosomer | |
DK3119397T3 (da) | Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser | |
DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
DK3119762T3 (da) | Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft | |
DK3851537T3 (da) | Behandling af hyperbilirubinæmi | |
DK3492632T3 (da) | Metoder til behandling af lithiumholdige materialer | |
DK3174858T3 (da) | Fremgangsmåde til fremstilling af pyrazoler | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
DK3185867T3 (da) | Krystalliseringsfremgangsmåde af aripiprazolderivater i forlængede frigivelsesformuleringer til behandling af skizofreni | |
DK3204398T3 (da) | Fremgangsmåder til fraseparering af gemcitabin-phosphat diastereoisomerer | |
DK3102213T3 (da) | Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser | |
DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
DK3191406T3 (da) | Fremgangsmåde til fremstilling af aluminiumchloridderivater | |
DK3265087T3 (da) | Fremgangsmåde til behandling med tradipitant | |
DK3233813T3 (da) | Fremgangsmåder til fremstilling af oxathiazin-lignende forbindelser | |
DK3325482T3 (da) | Fremgangsmåder til fremstilling af cytotoksiske benzodiazepinderivater |